- Home
- TCGL vs QNCX Comparison
TCGL vs QNCX Comparison
Compare TCGL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCGL
- QNCX
- Stock Information
- Founded
- TCGL 2015
- QNCX 2012
- Country
- TCGL Singapore
- QNCX United States
- Employees
- TCGL N/A
- QNCX N/A
- Industry
- TCGL EDP Services
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCGL Technology
- QNCX Health Care
- Exchange
- TCGL Nasdaq
- QNCX Nasdaq
- Market Cap
- TCGL 85.6M
- QNCX 100.4M
- IPO Year
- TCGL 2025
- QNCX 2019
- Fundamental
- Price
- TCGL $4.62
- QNCX $1.76
- Analyst Decision
- TCGL
- QNCX Strong Buy
- Analyst Count
- TCGL 0
- QNCX 6
- Target Price
- TCGL N/A
- QNCX $8.00
- AVG Volume (30 Days)
- TCGL 670.4K
- QNCX 446.8K
- Earning Date
- TCGL 11-16-2025
- QNCX 11-12-2025
- Dividend Yield
- TCGL N/A
- QNCX N/A
- EPS Growth
- TCGL N/A
- QNCX N/A
- EPS
- TCGL N/A
- QNCX N/A
- Revenue
- TCGL $2,274,647.00
- QNCX N/A
- Revenue This Year
- TCGL N/A
- QNCX N/A
- Revenue Next Year
- TCGL N/A
- QNCX N/A
- P/E Ratio
- TCGL N/A
- QNCX N/A
- Revenue Growth
- TCGL 7.80
- QNCX N/A
- 52 Week Low
- TCGL $3.95
- QNCX $0.72
- 52 Week High
- TCGL $5.43
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- TCGL N/A
- QNCX 49.53
- Support Level
- TCGL N/A
- QNCX $1.76
- Resistance Level
- TCGL N/A
- QNCX $1.95
- Average True Range (ATR)
- TCGL 0.00
- QNCX 0.18
- MACD
- TCGL 0.00
- QNCX -0.02
- Stochastic Oscillator
- TCGL 0.00
- QNCX 27.62
About TCGL TechCreate Group Ltd. Class A Ordinary Shares
TechCreate Group Ltd is a technology consultancy and advanced software solution provider offering a comprehensive range of payment, cybersecurity, and digital services and solutions. It serves large institutions, financial institutions and telecommunication companies, by providing them with payment, cybersecurity, and digital solutions such as, the development of RTE, RTP, API management and other services, such as cybersecurity defense, IT infrastructure, and cloud services. Its core business areas comprise: (1) the provision of professional services, (2) the sale of software licenses and maintenance licenses, and (3) the sale of hardware solutions.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.